Next Article in Journal
A Fatal Case of Immune Hyperhemolysis with Bone Marrow Necrosis in a Patient with Sickle Cell Disease
Previous Article in Journal
Can Ratio of Neutrophil-Tolymphocyte Count and Erythrocyte Sedimentation Rate in Diabetic Foot Infection Predict Osteomyelitis and/or Amputation?
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era

First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shin-Machi, Hirakata, Osaka 573-1010, Japan
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2017, 9(1), 16-18; https://doi.org/10.4081/hr.2017.6887
Submission received: 14 September 2016 / Revised: 23 October 2016 / Accepted: 28 December 2016 / Published: 23 February 2017

Abstract

The acronym CRAB summarizes the most typical clinical manifestations of multiple myeloma, these being hypercalcemia, renal failure, anemia, and bone disease. CRAB can be used to distinguish between active, symptomatic multiple myeloma and monoclonal gammopathy of undermined significance or smoldering myeloma. The distinction is relevant not only for classification and diagnosis but also for therapy. CRAB factors influence the prognosis of multiple myeloma. However, it is unclear whether the presence of CRAB factors has an influence on the prognosis of myeloma treated with novel agents. In the current study, patients with hypercalcemia and bone disease showed a significantly worse prognosis, whereas anemia and renal failure showed no difference in survival. Novel agents used for treatment of patients with renal failure suggested a favorable outcome compared with conventional therapy. Bone disease was the most common factor and may have the strongest prognostic value in symptomatic myeloma patients using novel agents.
Keywords: CRAB; symptomatic myeloma; novel agent; conventional therapy CRAB; symptomatic myeloma; novel agent; conventional therapy

Share and Cite

MDPI and ACS Style

Nakaya, A.; Fujita, S.; Satake, A.; Nakanishi, T.; Azuma, Y.; Tsubokura, Y.; Hotta, M.; Yoshimura, H.; Ishii, K.; Ito, T.; et al. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematol. Rep. 2017, 9, 16-18. https://doi.org/10.4081/hr.2017.6887

AMA Style

Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, Hotta M, Yoshimura H, Ishii K, Ito T, et al. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematology Reports. 2017; 9(1):16-18. https://doi.org/10.4081/hr.2017.6887

Chicago/Turabian Style

Nakaya, Aya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yoshiko Azuma, Yukie Tsubokura, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, and et al. 2017. "Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era" Hematology Reports 9, no. 1: 16-18. https://doi.org/10.4081/hr.2017.6887

APA Style

Nakaya, A., Fujita, S., Satake, A., Nakanishi, T., Azuma, Y., Tsubokura, Y., Hotta, M., Yoshimura, H., Ishii, K., Ito, T., & Nomura, S. (2017). Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematology Reports, 9(1), 16-18. https://doi.org/10.4081/hr.2017.6887

Article Metrics

Back to TopTop